Our Focus
Who We Are
Pipeline
Updates
Latest News and Events from Sophrosyne
Stay up to date on our products and research.
All
Press Releases
Publications
Corporate Info
Here's to Us Series
Reach Up Podcast Episode #3: Taking breakthrough science from lab to launch | Herm Cukier, CEO, Sophrosyne Pharmaceuticals
Nov 2, 2026
|
Corporate Info
Sophrosyne Corporate Deck
Oct 19, 2026
|
Corporate Info
Sophrosyne Pharmaceuticals Invited to Present at the Oppenheimer Private Life Sciences Company Showcase
Sep 29, 2026
|
Press Releases
Sophrosyne Pharmaceuticals Announces Acceptance of Late-Breaking Poster Presentation at the Global ISAM Conference
Sep 28, 2026
|
Press Releases
Sophrosyne Pharmaceuticals Further Expands its Novel NCE Portfolio for the Treatment of Alcohol Use Disorder (AUD)
Sep 8, 2026
|
Press Releases
Sophrosyne Pharmaceuticals Announces Dosing of First Subject in Multiple Ascending Dose Study for the Treatment of AUD
Jul 30, 2026
|
Press Releases
The Drinking Illusion
Jul 23, 2026
|
Here's to Us Series
Sophrosyne Pharmaceuticals Expands its Novel NCE Portfolio with Creation and Patent Filing of GLP-1 Combination
Jul 16, 2026
|
Press Releases
Sophrosyne Pharmaceuticals Appoints Renowned Hepatologist Dr. Ashwani Singal to its Scientific Advisory Board
Jul 13, 2026
|
Press Releases
Sophrosyne Pharmaceuticals Receives FDA Fast Track Designation for its Lead Product, SOPH-110S, for the Treatment of Alcohol Use Disorder (AUD)
Jun 18, 2026
|
Press Releases
Sophrosyne Pharmaceuticals Announces Dosing of First Subject in Phase I Study of Its Lead Asset for the Treatment of AUD
Apr 8, 2026
|
Press Releases
Sophrosyne Pharmaceuticals Invited to Present at the Oppenheimer Healthcare Life Sciences Conference
Feb 18, 2026
|
Press Releases
1
2
3
